Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Israel’s Taro Sues India’s Sun Over Sale Plans For Irish Unit

This article was originally published in PharmAsia News

Executive Summary

The canceled sale of India's Sun Pharma to Israel's Taro Pharma has led to a lawsuit filed in Israel over Sun efforts to stop the associated sale of Taro holdings in Ireland. Last month, Taro withdrew plans to acquire Sun for $460 million. The planned merger had involved Taro selling its Irish operations, but required Sun's consent, which Taro says Sun now refuses to give. Taro also has pending another suit against Sun involving alleged Sun efforts to increase its voting power in Taro. (Click here for more

You may also be interested in...

PharmAsia News Notable Notes: Citigroup Reiterates Buy On India’s Sun Pharma

NEW DELHI - Citigroup Global Markets reiterated its buy on Sun Pharma, India's largest drug company by market capitalization, saying a recent price dip related to a disputed merger attempt with Israel's Taro Pharma offers a "window of opportunity.

Ready, Set, Guidance: FDA Releases Final Details Ahead Of ASCA Pilot Launch

A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.

With Preservative-Free Alaway Eye Drops, Bausch Expands OTC Portfolio Of Planned Spin-Off

Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals. 




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts